Hepatitis C and interferon: fewer cases of liver cancer.
Data on the risk of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C participating in placebo-controlled trials of interferon have been published after 3 to 9 years of follow-up. Among patients with chronic hepatitis C and either fibrosis or cirrhosis, interferon greatly reduced the risk of hepatocellular carcinoma after 8 years or more, especially when viral load was below the limit of detection.
D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D057230:Limit of Detection; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control*; D012306:Risk; D013997:Time Factors; D019562:Viral Load
D000998:Antiviral Agents; D007372:Interferons